Carmine Therapeutics
We're proud to announce that Carmine Therapeutics was incorporated in Jan 2019 and it's a Boston-Singapore Esco Ventures X company, working on pioneering a powerful new class of medicines based on red blood cell extracellular vesicles (RBCEVs). In addition to the exciting technology, Carmine also has a strong scientific advisory board consisting of industry and scientific experts.
Prof. Harvey Lodish
Scientific Advisor
-
Professor, MIT; Founding Member, Whitehead Institute
-
Member of U.S. National Academy of Sciences
-
Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)
Prof. Minh Le
Scientific Advisor
-
Professor, MIT; Founding Member, Whitehead Institute
-
Member of U.S. National Academy of Sciences
-
Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)
Prof. Shi Jiahai
Scientific Advisor
-
Professor, MIT; Founding Member, Whitehead Institute
-
Member of U.S. National Academy of Sciences
-
Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)
Prof. Jianzhu Chen
Scientific Advisor
-
Professor, MIT; Founding Member, Whitehead Institute
-
Member of U.S. National Academy of Sciences
-
Founder and SAB of Genzyme (sold to Sanofi for USD20.2B), Millennium Pharma (sold to Takeda for USD9B), Rubius Therapeutics (preclinical IPO at USD1.8B)